Piper Sandler Reiterates Overweight Rating on NovoCure Ltd. (NVCR)
Tweet Send to a Friend
Piper Sandler analyst Jason Bednar reiterated an Overweight rating and $27.00 price target on NovoCure Ltd. (NASDAQ: NVCR).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
